<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181231</url>
  </required_header>
  <id_info>
    <org_study_id>201406016</org_study_id>
    <secondary_id>IND 123020</secondary_id>
    <secondary_id>IND 130774</secondary_id>
    <nct_id>NCT02181231</nct_id>
  </id_info>
  <brief_title>Buprenorphine Used With Treatment Resistant Depression in Older Adults</brief_title>
  <acronym>IRLGreyB</acronym>
  <official_title>Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reckitt Benckiser LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are conducting a research study to learn about the safety and benefit of
      using a medication called buprenorphine for patients with difficult to treat depression. This
      research study is testing whether combining two medications will be effective in treating
      depression when initial treatment with just one antidepressant does not relieve the
      depressive symptoms; this is what is called &quot;difficult to treat depression&quot; or &quot;treatment
      resistant depression&quot;. The two medications the investigators are using are: an
      anti-depressant medication called venlafaxine extended release (venlafaxine XR), which is the
      generic form of Effexor, and buprenorphine. Buprenorphine is a medication that is FDA
      approved for the treatment of opioid dependence. The investigators are testing whether adding
      buprenorphine to venlafaxine XR enhances treatment response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will consent approximately 100 participants, aged 50 and older, of both sexes and all
      races. Participation may last up to 32 weeks. We will utilize a clinical trial that has 3
      Phases. In Phase 1 we will treat participants with an approximate 12 week course of
      open-label venlafaxine XR. This is the same lead-in treatment as in our ongoing &quot;IRL Grey&quot;
      (&quot;Incomplete Response in Late Life Depression: Getting to Remission&quot;) multi-site R01 for
      late-life treatment resistant depression (LL-TRD), and we have found it to be highly
      successful. Participants who find relief from their depressive symptoms on venlafaxine XR
      alone will exit the study. Participants meeting criteria for an incomplete response (those
      still feeling depressed or withdrawn), will be randomly assigned to receive either low-dose
      buprenorphine or placebo augmentation of venlafaxine xr for 8 weeks (Phase 2), with the goal
      of achieving remission. Subjects will start at 0.2mg and titrate up as needed to 1.2mg.
      Subjects may undergo up to 2 MRI scans at the beginning and end of Phase 2 as well as
      cognitive testing at the same time points. At the conclusion of Phase 2, the blind will be
      broken for all participants. The participants who were on placebo will be able to begin
      taking buprenorphine immediately for Phase 3 (approximately 8 weeks). The participants who
      were already on buprenorphine in Phase 2 can continue to take it during Phase 3.
      Buprenorphine (BPN) will be tapered upon exiting the study, under the guidance of the P.I.
      The Phase 3 variations will allow all participants a chance to experience the benefits of
      buprenorphine (BPN). Efficacy and tolerability data will provide a clinically informative
      estimate of benefits and risks of buprenorphine augmentation for late-life treatment
      resistant depression (LL-TRD). We will randomize approximately 20 subjects into Phase 2.
      Additionally, we will collect buprenorphine (BPN) plasma levels on all those randomized to
      explore a dose-effect relationship on treatment response.

      A small pilot study (ages 21 and up) of up to 15 healthy control subjects will be studied
      over an approximate 2 week period in order to ensure all of our procedures are working and to
      determine that there are clinical effects from buprenorphine. Control subjects will undergo a
      baseline PET/MRI before taking buprenorphine. At least 24 hours after the imaging, control
      subjects will receive a small dose of BPN starting at 0.2 mg/day and will titrate up as
      tolerated to 1.2 mg/day for the first week. Each subject will remain at approximately 1.2
      mg/day for the duration of the study. At the end of the study, subjects will undergo a second
      PET/MRI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measure of depression severity, range of 0-60, with higher scores indicating more severe depression. We calculated the mean change in depression for both groups using baseline MADRS and week 8 MADRS scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)</measure>
    <time_frame>Week 1 and week 8</time_frame>
    <description>Three item side effect scale used to assess frequency and intensity of side effects (range 0-6 for each item). We calculated the total score of all three items (range 0-18) with lower numbers indicating less frequency.
We calculated the mean score at baseline and week 8 (final timepoint).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antidepressant Side Effect Checklist (ASEC)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measure of side effects, consisting of 21 items, ranging from 0-3 (0 indicates no side effect, 3 indicates severe side effect). We calculated the total final score for the 21 items (total range is 0-63). A higher total number represents a greater severity in reported side effects. We calculated the mean change in side effects for both groups using baseline and 8 week data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suicide Ideation Scale (SIS)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>A 19 item scale used to measure the presence or absence of suicidal ideations and the degree of severity of suicidal ideas. For this study, we computed the total score for all 19 items (total range 0-90). Higher scores represent a worse outcome. We also calculated the mean change in suicidal ideation for both groups using baseline and week 8 (final timepoint).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory-Anxiety Subscale (BSI)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measure of anxiety. Six anxiety symptoms are rated based on how distressed the subject is for each symptom. The range for each symptom is 0-4, with 4 representing extreme distress. We computed the mean of the final BSI score (range 0-24), with a lower number indicating a better outcome. We also calculated the mean change in anxiety for both groups using baseline and Phase 2 week 8 (final time point) data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Scale of Pain (NRS-P)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measure used to assess pain, ranging from 0-10, with 10 being the worst possible pain.
We calculated the mean change in pain for both groups using baseline and week 8 (last time point).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>venlafaxine plus buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>venlafaxine XR plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine XR</intervention_name>
    <description>slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks</description>
    <arm_group_label>venlafaxine XR plus placebo</arm_group_label>
    <arm_group_label>venlafaxine plus buprenorphine</arm_group_label>
    <other_name>Effexor XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine</intervention_name>
    <description>randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd</description>
    <arm_group_label>venlafaxine plus buprenorphine</arm_group_label>
    <other_name>Temgesic</other_name>
    <other_name>Subutex</other_name>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.</description>
    <arm_group_label>venlafaxine XR plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Main Study:

          1. Age &gt; or = to 50 years.

          2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the Structured
             Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders
             (SCID-IV).

          3. Montgomery Asberg Depression Rating Scale (MADRS) &gt;/= to 15.

          4. Has or agrees to establish a clinical relationship with primary care physician (PCP).

          5. Availability of an informant (e.g., emergency contact).

        Exclusion Criteria:

          1. Inability to provide informed consent.

          2. Depressive symptoms not severe enough (i.e., MADRS &lt; 15) at the baseline assessments

          3. Dementia, as defined by Mini Mental State Exam (3MS) &lt; 84 and clinical evidence of
             dementia (e.g., memory impairment, executive dysfunction, agnosia, apraxia, aphasia,
             with functional impairment).

          4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective
             disorder, schizophreniform disorder, delusional disorder, or current psychotic
             symptoms, as diagnosed by the SCID.

          5. Abuse of or dependence on alcohol or other substances within the past 3 months as
             determined by SCID, and confirmed by study physician interview.

          6. Drinking 15 or more drinks per week or consuming 5 or more drinks on any one occasion
             in the past week.

          7. High risk for suicide (e.g., active SI and/or current/recent intent or plan) and
             unable to be managed safely in the clinical trial (e.g., unwilling to be
             hospitalized). Urgent psychiatric referral will be made in these cases.

          8. Contraindication to venlafaxine XR or BPN as determined by PCP and study physician
             including history of intolerance of either venlafaxine XR or BPN in the study target
             dosage range (venlafaxine XR at up to 300 mg/day; BPN at up to 2 mg/day).

          9. Inability to communicate in English (i.e., interview cannot be conducted without an
             interpreter; subject largely unable to understand questions and cannot respond in
             English).

         10. Non-correctable clinically significant sensory impairment (i.e., cannot hear well
             enough to cooperate with interview).

         11. Unstable medical illness, including delirium, uncontrolled diabetes mellitus,
             hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that
             are not under medical management. This will be determined based on information from
             the patient's personal physician and study physician's clinical judgment. Referral to
             the patient's personal physician or to a general practitioner will be made in these
             cases.

         12. Subjects taking psychotropic medications that cannot be safely tapered and
             discontinued prior to study initiation. The following exceptions are allowed if they
             have been taken at a stable dose for at least 4 weeks prior to study entry and there
             is not a plan to change the dose during the next 28 weeks: benzodiazepines up to 2
             mg/d lorazepam equivalent; other sedative-hypnotics (e.g., zolpidem, zaleplon,
             eszopiclone); gabapentin if prescribed for non-psychiatric indication (e.g.,
             neuropathy).

         13. History of opioid abuse or dependence.

         14. Severe pain, defined as &gt; 7 on 0-10 numeric rating scale for pain.

         15. Concomitant use of strong or moderate CYP3A4 inhibitor (indinavir, nelfinavir,
             ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir,
             telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil,
             diltiazem).

         16. Refusal to stop all opioids (to avoid precipitating opioid withdrawal).

         17. Hepatic impairment

         18. Estimated Glomerular Filtration Rate (GFR) &lt; 20 ml/min.

         19. Inability/refusal to identify a person as an emergency contact.

         20. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric J Lenze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>June 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2019</results_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Eric Lenze</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>older adult</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>Effexor XR</keyword>
  <keyword>treatment resistant</keyword>
  <keyword>venlafaxine</keyword>
  <keyword>Saint Louis</keyword>
  <keyword>late life</keyword>
  <keyword>major depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02181231/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Drug: low dose buprenorphine (range .2mg/day-2.0mg/day)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Drug: placebo Matched placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine</title>
          <description>Drug: buprenorphine Low-dose buprenorphine (range 0.2mg/day-2.0mg/day)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Drug: matched placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" spread="9.5"/>
                    <measurement group_id="B2" value="60.8" spread="8.8"/>
                    <measurement group_id="B3" value="64" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>Measure of depression severity, range of 0-60, with higher scores indicating more severe depression. We calculated the mean change in depression for both groups using baseline MADRS and week 8 MADRS scores.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Drug: low dose buprenorphine (range .2mg/day-2.0mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: placebo Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>Measure of depression severity, range of 0-60, with higher scores indicating more severe depression. We calculated the mean change in depression for both groups using baseline MADRS and week 8 MADRS scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in MADRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="6.8"/>
                    <measurement group_id="O2" value="-5.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final MADRS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="6.7"/>
                    <measurement group_id="O2" value="15.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)</title>
        <description>Three item side effect scale used to assess frequency and intensity of side effects (range 0-6 for each item). We calculated the total score of all three items (range 0-18) with lower numbers indicating less frequency.
We calculated the mean score at baseline and week 8 (final timepoint).</description>
        <time_frame>Week 1 and week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Drug: low dose buprenorphine (range .2mg/day-2.0mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: placebo Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)</title>
          <description>Three item side effect scale used to assess frequency and intensity of side effects (range 0-6 for each item). We calculated the total score of all three items (range 0-18) with lower numbers indicating less frequency.
We calculated the mean score at baseline and week 8 (final timepoint).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="3.9"/>
                    <measurement group_id="O2" value="1.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final FIBSER Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.0"/>
                    <measurement group_id="O2" value=".5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antidepressant Side Effect Checklist (ASEC)</title>
        <description>Measure of side effects, consisting of 21 items, ranging from 0-3 (0 indicates no side effect, 3 indicates severe side effect). We calculated the total final score for the 21 items (total range is 0-63). A higher total number represents a greater severity in reported side effects. We calculated the mean change in side effects for both groups using baseline and 8 week data.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Drug: low dose buprenorphine (range .2mg/day-2.0mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: placebo Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Antidepressant Side Effect Checklist (ASEC)</title>
          <description>Measure of side effects, consisting of 21 items, ranging from 0-3 (0 indicates no side effect, 3 indicates severe side effect). We calculated the total final score for the 21 items (total range is 0-63). A higher total number represents a greater severity in reported side effects. We calculated the mean change in side effects for both groups using baseline and 8 week data.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in ASEC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="7.0"/>
                    <measurement group_id="O2" value="1.8" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final ASEC score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="7.6"/>
                    <measurement group_id="O2" value="8.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suicide Ideation Scale (SIS)</title>
        <description>A 19 item scale used to measure the presence or absence of suicidal ideations and the degree of severity of suicidal ideas. For this study, we computed the total score for all 19 items (total range 0-90). Higher scores represent a worse outcome. We also calculated the mean change in suicidal ideation for both groups using baseline and week 8 (final timepoint).</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Drug: low dose buprenorphine (range .2mg/day-2.0mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: placebo Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Suicide Ideation Scale (SIS)</title>
          <description>A 19 item scale used to measure the presence or absence of suicidal ideations and the degree of severity of suicidal ideas. For this study, we computed the total score for all 19 items (total range 0-90). Higher scores represent a worse outcome. We also calculated the mean change in suicidal ideation for both groups using baseline and week 8 (final timepoint).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in SIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.2" spread="4.7"/>
                    <measurement group_id="O2" value="-1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final SIS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="3.5"/>
                    <measurement group_id="O2" value="4.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Symptom Inventory-Anxiety Subscale (BSI)</title>
        <description>Measure of anxiety. Six anxiety symptoms are rated based on how distressed the subject is for each symptom. The range for each symptom is 0-4, with 4 representing extreme distress. We computed the mean of the final BSI score (range 0-24), with a lower number indicating a better outcome. We also calculated the mean change in anxiety for both groups using baseline and Phase 2 week 8 (final time point) data.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Drug: low dose buprenorphine (range .2mg/day-2.0mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: placebo Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Symptom Inventory-Anxiety Subscale (BSI)</title>
          <description>Measure of anxiety. Six anxiety symptoms are rated based on how distressed the subject is for each symptom. The range for each symptom is 0-4, with 4 representing extreme distress. We computed the mean of the final BSI score (range 0-24), with a lower number indicating a better outcome. We also calculated the mean change in anxiety for both groups using baseline and Phase 2 week 8 (final time point) data.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in BSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7" spread="2.8"/>
                    <measurement group_id="O2" value="0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final BSI score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="3.7"/>
                    <measurement group_id="O2" value="2.7" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numeric Scale of Pain (NRS-P)</title>
        <description>Measure used to assess pain, ranging from 0-10, with 10 being the worst possible pain.
We calculated the mean change in pain for both groups using baseline and week 8 (last time point).</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Drug: low dose buprenorphine (range .2mg/day-2.0mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Drug: placebo Matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Scale of Pain (NRS-P)</title>
          <description>Measure used to assess pain, ranging from 0-10, with 10 being the worst possible pain.
We calculated the mean change in pain for both groups using baseline and week 8 (last time point).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in NRS-P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.4"/>
                    <measurement group_id="O2" value="-1.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final NRS-P score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.0"/>
                    <measurement group_id="O2" value="2.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine</title>
          <description>Drug: low dose buprenorphine (range .2mg/day-2.0mg/day)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Drug: placebo Matched placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Hospitalized for emergency cardiac catheterization and insertion of cardiac stent. Diagnosed with partially closed blood vessel due to scleroderma diagnosis.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpatations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased intestinal gas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Room spinning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased body temperature</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Swollen hands and ankles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Falls</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary problems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Lenze</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-1671</phone>
      <email>lenzee@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

